Proteomics

Dataset Information

0

Translatome proteomics of human AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib

ABSTRACT: Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25% of acute myeloid leukemia (AML) patients and lead to constitutive activation of FLT3, driving leukemia cell survival and proliferation. Quizartinib, crenolanib and gilteritinib are second-generation FLT3 inhibitors (FLT3i) in phase III trials or clinical use for the targeted treatment of FLT3-ITD+ AML. However, they demonstrated only limited benefit and were not curative. A full understanding of cellular resistance factors contributing to this poor response is lacking. Here, we examined cell-autonomous pathways modulated by FLT3i using global translatome and phosphoproteome proteomics to identify non-genetic resistance mechanisms.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Suspension Culture, Leukocyte

DISEASE(S): Acute Leukemia

SUBMITTER: Sebastian Koschade  

LAB HEAD: Christian Münch

PROVIDER: PXD023125 | Pride | 2022-08-25

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20200520_GT_SK_3-3_Plex1_F.msf Msf
20200520_GT_SK_3-3_Plex1_F1.raw Raw
20200520_GT_SK_3-3_Plex1_F10.raw Raw
20200520_GT_SK_3-3_Plex1_F11.raw Raw
20200520_GT_SK_3-3_Plex1_F12.raw Raw
Items per page:
1 - 5 of 125
altmetric image

Publications

Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25 % of acute myeloid leukemia (AML) patients, drive leukemia progression and confer a poor prognosis. Primary resistance to FLT3 kinase inhibitors (FLT3i) quizartinib, crenolanib and gilteritinib is a frequent clinical challenge and occurs in the absence of identifiable genetic causes. This suggests that adaptive cellular mechanisms mediate primary resistance to on-target FLT3i therapy. Here, we systematically inve  ...[more]

Similar Datasets

Proteomics Phosphoproteomics of human MV4-11 AML cells treated with Gilteritinib
2022-08-25 | PXD023123 | Pride
Proteomics Phosphoproteomics of primary human FLT3-ITD+ AML cells treated with gilteritinib
2022-08-25 | PXD034080 | Pride
Proteomics Alkynyl nicotinamides with antileukemic activity to treat poor prognosis AM
2022-12-07 | MSV000090855 | MassIVE
Proteomics Translatome proteomics of primary human FLT3-ITD+ AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
2022-08-25 | PXD034081 | Pride
Transcriptomics Mitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment
2025-03-19 | GSE276384 | GEO
Proteomics Phosphoproteomic characterization of primary AML samples and relevance for response towards FLT3-inhibitors
2021-09-10 | PXD024235 | Pride
Transcriptomics shCDK9 or shDHODH sensitizes cells to gilteritinib treatment by altering transcriptomes of AML cells
2022-09-21 | GSE185519 | GEO
Transcriptomics Effect of Gilteritinib, Metformin and Combination treatments on gene expression in MOLM13-RES cells
2024-06-14 | GSE244855 | GEO
Transcriptomics Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia (RNA-Seq II)
2021-07-22 | GSE180181 | GEO
Genomics Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia
2021-07-07 | GSE179421 | GEO